For nearly eight years, Alnylam has enjoyed something almost unheard of in biotech: a drug with no true rival for a fatal heart condition. That exclusivity has been the foundation of the company’s entire valuation. Now, that foundation is showing cracks.
The stock closed Friday at EUR 177.30, roughly flat on the day. But the damage over recent weeks tells the real story. Shares have lost nearly half their value since the start of the year and are down almost 58 percent from the October peak of EUR 421.90. The current price sits barely three percent above the 52-week low.
A Record Quarter That Couldn’t Save the Stock
The disconnect between business performance and market reaction is striking. Alnylam posted second-quarter revenue of $1.17 billion, up 74 percent year over year. The heart therapy Amvuttra crossed the billion-dollar quarterly sales mark for the first time — a genuine milestone for the RNAi specialist.
Yet the stock tumbled more than 25 percent within a week of the July 30 earnings release. The culprit wasn’t the numbers themselves but the guidance attached to them. Management cut its full-year 2026 sales outlook for the TTR franchise, citing a normalization of demand. The early surge had been inflated by pent-up need among second-line patients who had long waited for a new option; that pool has now largely been served.
The market’s response suggests it’s treating this normalization as something more sinister — a structural breakdown rather than a post-surge settling. One could argue the reaction is overdone: a return to baseline after an exceptional period is not the same as collapsing demand. But the tape doesn’t care about such distinctions right now.
The Competitive Threat Looms Larger
The real story isn’t in the rearview mirror — it’s in the competitive landscape. AstraZeneca and Ionis are set to present full data from their heart failure study with the rival drug eplontersen at the European Society of Cardiology congress in August 2026. That presentation could reopen the question of whether eplontersen can hold its own as a first-line therapy in the cardiomyopathy form of the disease.
A published subgroup analysis offers an early glimpse of potential vulnerabilities in Alnylam’s moat. Patients receiving eplontersen as monotherapy showed clear cardiovascular benefit. But for those already on a stabilizer, that added benefit failed to materialize.
For now, market structure still favors Alnylam. Industry analysis is blunt: Alnylam remains the only approved gene-silencing option for ATTR-CM, but investors should treat that exclusivity as provisional rather than guaranteed. That single sentence captures the debate playing out in the share price — is this a temporary dent in an otherwise dominant franchise, or the first crack in a monopoly that justified a much higher valuation?
Should investors sell immediately? Or is it worth buying Alnylam?
Technicals Paint a Nervous Picture
The chart reflects the unease. The 14-day RSI has fallen to 23, deep in oversold territory. Meanwhile, annualized 30-day volatility has spiked to roughly 91 percent — levels more typical of binary clinical trial outcomes than an established commercial company generating billions in quarterly revenue.
The consensus analyst price target stands at EUR 374.50, implying more than a doubling from Friday’s close. That gap can be read two ways: either analysts are behind the curve on the new competitive reality, or the market has over-punished a single disappointing guidance revision.
Even JPMorgan and Oppenheimer, which trimmed their price targets after the guidance cut, maintained positive ratings, citing the long-term potential of the ATTR cardiomyopathy market. The current market capitalization of roughly EUR 23.8 billion arguably fails to reflect Alnylam’s position as a pioneer in the RNAi drug class.
The Bigger RNAi Bet
Rather than defending Amvuttra alone, Alnylam is pushing its pipeline forward. The follow-up candidate nucresiran is designed to ensure the company’s own franchise doesn’t become technologically obsolete. Earlier-stage programs in hypertension, Alzheimer’s, and blood clotting disorders round out the long-term RNAi thesis.
None of that changes the immediate trading picture. No company-specific catalysts are scheduled before the ESC presentations in August, so the coming days are likely to be shaped by continued reassessment of competitive data and digestion of the lowered guidance.
What to Watch
Technically, all eyes are on the 52-week low at EUR 172.15. Holding that level could open the door to a genuine consolidation, with the oversold condition potentially fueling a bounce toward the 50-day moving average near EUR 251. A break below, however, could extend the capitulation that began with the earnings release.
The deeper answer won’t come from any single trading session. It will arrive on a cardiology congress stage, far from Wall Street, when eplontersen’s full dataset takes center stage. Until then, Alnylam remains a stock where the fundamental story appears intact — but the price has yet to prove it has digested last week’s loss of confidence.
Ad
Alnylam Stock: Buy or Sell?! New Alnylam Analysis from August 2 delivers the answer:
The latest Alnylam figures speak for themselves: Urgent action needed for Alnylam investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 2.
Alnylam: Buy or sell? Read more here...
